172 related articles for article (PubMed ID: 36542104)
21. [Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: outcomes and prognostic factors].
Su XH; Yao JF; Zhang GX; He Y; Wei JL; Ma QL; Yang DL; Huang Y; Zhai WH; Liang C; Li G; Chen X; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1024-1030. PubMed ID: 29365394
[No Abstract] [Full Text] [Related]
22. [Survival efficacy of MDS/AML patients with TP53 abnormal received allogeneic hematopoietic stem cell transplantation].
Feng D; Wang MY; Liu J; Zhang HX; Chen X; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):222-229. PubMed ID: 37356984
[No Abstract] [Full Text] [Related]
23. Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy.
Araie H; Arai Y; Kida M; Aoki J; Uchida N; Doki N; Fukuda T; Tanaka M; Ozawa Y; Sawa M; Katayama Y; Matsuo Y; Onizuka M; Kanda Y; Kawakita T; Kanda J; Atsuta Y; Yanada M;
Ann Hematol; 2023 Oct; 102(10):2879-2893. PubMed ID: 37477669
[TBL] [Abstract][Full Text] [Related]
24. Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia.
Oran B; Dolan M; Cao Q; Brunstein C; Warlick E; Weisdorf D
Biol Blood Marrow Transplant; 2011 Mar; 17(3):356-64. PubMed ID: 20553926
[TBL] [Abstract][Full Text] [Related]
25. Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study.
Sharma A; Galimard JE; Pryce A; Bhoopalan SV; Dalissier A; Dalle JH; Locatelli F; Jubert C; Mirci-Danicar O; Kitra-Roussou V; Bertrand Y; Fagioli F; Rialland F; Biffi A; Wynn RF; Michel G; Tambaro FP; Al-Ahmari A; Tbakhi A; Furness CL; Diaz MA; Sedlacek P; Bodova I; Faraci M; Rao K; Kleinschmidt K; Petit A; Gibson B; Bhatt NS; Kalwak K; Corbacioglu S
Bone Marrow Transplant; 2024 Apr; 59(4):451-458. PubMed ID: 38225386
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of complex and/or monosomal karyotypes in post-transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach.
Jo T; Arai Y; Oshima S; Kondo T; Harada K; Uchida N; Doki N; Fukuda T; Tanaka M; Ozawa Y; Kuriyama T; Ikegame K; Katayama Y; Ota S; Ara T; Kawakita T; Onizuka M; Ichinohe T; Atsuta Y; Yanada M;
Br J Haematol; 2023 Jul; 202(2):356-368. PubMed ID: 37211753
[TBL] [Abstract][Full Text] [Related]
27. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
28. Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study.
Grosicki S; Holowiecki J; Kuliczkowski K; Skotnicki A; Hellmann A; Kyrcz-Krzemien S; Dmoszynska A; Sułek K; Kloczko J; Jedrzejczak WW; Warzocha K; Zdziarska B; Wierzbowska A; Pluta A; Komarnicki M; Giebel S
Am J Hematol; 2015 Oct; 90(10):904-9. PubMed ID: 26149802
[TBL] [Abstract][Full Text] [Related]
29. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution.
Lin CH; Chen TC; Shih YH; Chou CW; Hsu CY; Li PH; Teng CJ
J Int Med Res; 2022 Feb; 50(2):3000605221078466. PubMed ID: 35187981
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype.
Poiré X; Labopin M; Polge E; Ganser A; Socié G; Gedde-Dahl T; Forcade E; Finke J; Chalandon Y; Bulabois CE; Yakoub-Agha I; Aljurf M; Kröger N; Blau IW; Nagler A; Esteve J; Mohty M
Bone Marrow Transplant; 2024 Feb; 59(2):264-269. PubMed ID: 38092959
[TBL] [Abstract][Full Text] [Related]
31. [Effect of NCCN (2015) risk stratification on prognosis of patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Wang H; Liu HX; Wang T; Tong CR; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):44-49. PubMed ID: 28219225
[No Abstract] [Full Text] [Related]
32. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.
Zhou L; An J; Hou C; Ding Z; Qiu H; Tang X; Sun A; Chen S; Xu Y; Liu T; Wu D
Hematology; 2021 Dec; 26(1):340-347. PubMed ID: 33840380
[No Abstract] [Full Text] [Related]
34. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
[TBL] [Abstract][Full Text] [Related]
35. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
Fang J; Zhang R; Wang H; Hong M; Wu Q; Nie D; You Y; Zhong Z; Li W; Hu Y; Xia L
Leuk Res; 2016 Jul; 46():61-8. PubMed ID: 27131062
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation.
Gao Y; Wu H; Shi Z; Gao F; Shi J; Luo Y; Yu J; Lai X; Fu H; Liu L; Huang H; Zhao Y
Bone Marrow Transplant; 2023 Aug; 58(8):863-873. PubMed ID: 37120616
[TBL] [Abstract][Full Text] [Related]
37. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
38. Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.
Hemmati PG; Schulze-Luckow A; Terwey TH; le Coutre P; Vuong LG; Dörken B; Arnold R
Eur J Haematol; 2014 Feb; 92(2):102-10. PubMed ID: 24138573
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic analysis of allogeneic hematopoietic stem-cell transplantation in 47 patients with acute myeloid leukemia and MLL rearrangement].
Jiang SH; Hou C; Chen N; Chen SF; Qiu HY; Xu Y; Chen SN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):558-562. PubMed ID: 30122014
[No Abstract] [Full Text] [Related]
40. How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML.
Gutman JA
Best Pract Res Clin Haematol; 2022 Dec; 35(4):101411. PubMed ID: 36517129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
